Evotec
Tim James is an accomplished professional in the field of computational chemistry and research informatics, currently serving as Vice President and Head of In Silico R&D and Data Science at Evotec since June 2012. With a strong background in computational modeling techniques applied across various therapeutic areas such as inflammation, oncology, and immunology, Tim James has contributed to significant scientific progress and operational leadership within the Research Informatics group. Prior experiences include roles at Prosidion Ltd, where Tim James advanced computational systems for polypharmacology, and at Trinity College Dublin, where collaborations with prestigious institutions like the NIH and IBM were pivotal in developing computer-aided drug design methodologies. Tim James holds a PhD in Theoretical Chemistry and a BA in Natural Sciences from the University of Cambridge.
This person is not in any teams
This person is not in any offices
Evotec
5 followers
Evotec AG is a drug discovery and development company. The Company operates through two segments. The EVT Execute segment provides standalone drug discover services on a typical fee-for-service basis or integrated drug discovery collaborations on partners' target through a range of commercial structures, including research fees, milestones and/or royalties. The EVT Innovate segment develops drug discovery programs and assets, both internally or through academic collaborations. The Company seeks to partner these into collaborations in return for upfront payments, ongoing research payments. It consists of all partnerships derived from its internally developed assets and platforms and its participations in certain companies. It includes clinical initiations and progress of clinical pipeline within partnerships; expansion of academic BRIDGE network; research and development (R&D) progress with CureX/Target X initiatives, and focuses on induced pluripotent stem cells (iPSC) platform.